Skip to main content
Premium Trial:

Request an Annual Quote

AxCell Biosciences

Premium

The US Patent and Trademark office has awarded AxCell Biosciences US patent 6,309,820 entitled “Polypeptides Having a Functional Domain of Interest and Methods of Identifying and Using Same.” The patent, with 9 claims, covers the company’s method for identifying SH3 domain-containing proteins from human cDNA expression libraries, and is the first patent awarded for AxCell’s Cloning of Ligand Targets proteomics technology. In previous studies, researchers have associated proteins containing SH3 domains with cancer, diabetes, and diseases of the central nervous system. “This technology permits the use of ligands — small peptide sequences that bind to larger domain units within proteins — to discover new domains and ultimately new proteins that may be useful as drug targets,” said AxCell CEO John Rodwell in a statement. AxCell is currently building its ProChart database of protein-protein interactions involved in cell signaling.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.